Latest On vTv Therapeutics Inc (VTVT):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-24 23:27 EST | News | vTv gains 13% on patent win for potential brain tumor pill | N/A |  |
| 2023-05-12 02:13 EST | News | vTv Therapeutics GAAP EPS of -$0.06 beats by $0.05 | N/A | |
| 2022-12-13 14:03 EST | News | vTv Therapeutics names Steven Tuch as CFO | N/A | |
| 2022-11-11 01:03 EST | News | vTv Therapeutics GAAP EPS of -$0.05 | N/A | |
| 2022-08-16 16:02 EST | News | vTv Therapeutics GAAP EPS of -$0.04 | N/A | |
About vTv Therapeutics Inc (VTVT):
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates to fill unmet medical needs. The company is developing TTP399, an orally administered, small molecule, liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant PDE4 inhibitor that addresses inflammatory diseases. It is also involved in the clinical development of other programs, including a small molecule GLP-1r agonist; the PDE4 inhibitor; HPP737, a PPAR-delta agonist; and an Nrf2 activator through partnerships with pharmaceutical partners. The company has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated read more...receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; Novo Nordisk A/S; and Columbia University. The company was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.
General
- Name vTv Therapeutics Inc
- Symbol VTVT
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 25
- Fiscal Year EndDecember
- IPO Date2015-07-30
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.vtvtherapeutics.com
Valuation
- Price/Sales (Trailing 12 Mt.) 19.84
- Enterprise Value Revenue 33.19
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$0.49
- Profit Margin -133%
- Operating Margin -185%
- Return on Assets -62%
- Revenue 6.41 million
- Earnings Per Share -$0.56
- Revenue Per Share $0.14
- Gross Profit -4601000
- Quarterly Earnings Growth 91314.3%
Highlights
- Market Capitalization 245.16 million
- EBITDA -10758000
- Analyst Target Price $6.75
- Book Value Per Share -$1.67
Share Statistics
- Shares Outstanding 54.55 million
- Shares Float 20.73 million
- % Held by Insiders 7238%
- % Held by Institutions 8.01%
- Shares Short 2.52 million
- Shares Short Prior Month 3.06 million
- Short Ratio 0.37
- Short % of Float 11%
- Short % of Shares Outstanding 3%
Technicals
- Beta -1.85
- 52 Week High $3.59
- 52 Week Low $1.5
- 50 Day Moving Average 2.54
- 200 Day Moving Average 2.09
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
vTv Therapeutics Inc (VTVT) Dividend Calendar:
vTv Therapeutics Inc (VTVT) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
vTv Therapeutics Inc (VTVT) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
vTv Therapeutics Inc (VTVT) Chart:
vTv Therapeutics Inc (VTVT) News:
Below you will find a list of latest news for vTv Therapeutics Inc (VTVT) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
vTv Therapeutics Inc (VTVT) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest VTVT Trades:
vTv Therapeutics Inc (VTVT) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-05 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-11-05 | 8-K (Current report) | |
| 2020-10-26 | 8-K (Current report) | |
| 2020-10-02 | 8-K (Current report) | |
| 2020-09-03 | 3 (Initial statement of beneficial ownership of securities) | |
| 2020-09-01 | 8-K (Current report) | |
| 2020-08-03 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-08-03 | 8-K (Current report) | |
| 2020-08-03 | S-8 (Securities to be offered to employees in employee benefit plans) | |
| 2020-06-26 | 8-K (Current report) | |
| 2020-06-26 | 8-K (Current report) | |
| 2020-06-15 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-15 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-15 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-15 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-15 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-15 | 8-K (Current report) | |
| 2020-05-22 | DEFA14A (Additional definitive proxy soliciting materials and Rule 14(a)(12) material) | |
| 2020-05-18 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-05-12 | SC 13D/A (General statement of acquisition of beneficial ownership) | |
vTv Therapeutics Inc (VTVT) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of vTv Therapeutics Inc (VTVT). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 7238%
Institutional Ownership: 801%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-05-15 | HERSH KOZLOV | Director | Buy | 10,000.00 | 3.00 | 30,000.00 | 15,000.00 | |
| 2020-05-12 | RONALD O PERELMAN | 10% Share Holder | Buy | 625,000.00 | 1.60 | 1,000,000.00 | 34,731,212.00 | |
| 2020-03-10 | JEFFREY B KINDLER | Director | Buy | 11,667.00 | 35,000.00 | | ||
| 2020-02-25 | RONALD O PERELMAN | 10% Share Holder | Buy | 1,250,000.00 | 1.60 | 2,000,000.00 | 34,106,212.00 | |
| 2020-01-28 | RONALD O PERELMAN | 10% Share Holder | Buy | 1,250,000.00 | 1.60 | 2,000,000.00 | 32,856,212.00 | |
| 2020-01-07 | RONALD O PERELMAN | 10% Share Holder | Buy | 1,250,000.00 | 1.60 | 2,000,000.00 | 31,606,212.00 | |
| 2019-12-18 | RONALD O PERELMAN | 10% Share Holder | Buy | 1,369,863.00 | 1.46 | 1,999,999.98 | 30,356,212.00 | |
| 2019-11-26 | RONALD O PERELMAN | 10% Share Holder | Buy | 1,369,863.00 | 1.46 | 1,999,999.98 | 28,986,349.00 | |
| 2019-11-12 | RONALD O PERELMAN | 10% Share Holder | Buy | 1,369,863.00 | 1.46 | 1,999,999.98 | 27,616,486.00 | |
| 2019-10-24 | RONALD O PERELMAN | 10% Share Holder | Buy | 1,369,863.00 | 1.46 | 1,999,999.98 | 26,246,623.00 | |
| 2019-09-27 | RONALD O PERELMAN | 10% Share Holder | Buy | 1,369,863.00 | 1.46 | 1,999,999.98 | 24,876,760.00 | |
| 2019-09-18 | RONALD O PERELMAN | 10% Share Holder | Buy | 606,061.00 | 1.65 | 1,000,000.65 | 23,506,897.00 | |
| 2019-09-13 | HERSH KOZLOV | Director | Buy | 5,000.00 | 1.65 | 8,250.00 | 5,000.00 | |
| 2019-09-11 | RONALD O PERELMAN | 10% Share Holder | Buy | 606,061.00 | 1.65 | 1,000,000.65 | 22,900,836.00 | |
| 2019-09-04 | RONALD O PERELMAN | 10% Share Holder | Buy | 606,061.00 | 1.65 | 1,000,000.65 | 22,294,775.00 | |
| 2019-08-22 | RONALD O PERELMAN | 10% Share Holder | Buy | 50,000.00 | 1.38 | 69,000.00 | 21,688,714.00 | |
| 2019-08-19 | RONALD O PERELMAN | 10% Share Holder | Buy | 150,000.00 | 1.31 | 195,900.00 | 21,638,714.00 | |
| 2019-08-06 | RONALD O PERELMAN | 10% Share Holder | Buy | 1,212,121.00 | 1.65 | 1,999,999.65 | 21,488,714.00 | |
| 2019-07-09 | RONALD O PERELMAN | 10% Share Holder | Buy | 1,212,121.00 | 1.65 | 1,999,999.65 | 20,276,593.00 | |
| 2019-06-25 | RONALD O PERELMAN | 10% Share Holder | Buy | 1,212,121.00 | 1.65 | 1,999,999.65 | 19,064,472.00 | |